Rhumbline Advisers Grows Stock Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Rhumbline Advisers raised its stake in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 32.6% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 76,833 shares of the company’s stock after purchasing an additional 18,897 shares during the quarter. Rhumbline Advisers’ holdings in EyePoint Pharmaceuticals were worth $668,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Ameritas Investment Partners Inc. grew its holdings in EyePoint Pharmaceuticals by 44.0% in the first quarter. Ameritas Investment Partners Inc. now owns 3,719 shares of the company’s stock worth $77,000 after purchasing an additional 1,136 shares during the period. Essex Investment Management Co. LLC increased its holdings in EyePoint Pharmaceuticals by 1.5% during the first quarter. Essex Investment Management Co. LLC now owns 149,819 shares of the company’s stock valued at $3,097,000 after buying an additional 2,278 shares during the last quarter. Janney Montgomery Scott LLC increased its stake in shares of EyePoint Pharmaceuticals by 26.5% in the 1st quarter. Janney Montgomery Scott LLC now owns 18,040 shares of the company’s stock worth $373,000 after purchasing an additional 3,780 shares in the last quarter. American International Group Inc. raised its stake in shares of EyePoint Pharmaceuticals by 38.4% in the first quarter. American International Group Inc. now owns 18,378 shares of the company’s stock worth $380,000 after buying an additional 5,101 shares during the period. Finally, China Universal Asset Management Co. Ltd. raised its stake in EyePoint Pharmaceuticals by 129.9% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,393 shares of the company’s stock worth $194,000 after acquiring an additional 5,308 shares during the period. Hedge funds and other institutional investors own 99.41% of the company’s stock.

EyePoint Pharmaceuticals Trading Up 0.6 %

Shares of NASDAQ EYPT opened at $8.34 on Wednesday. EyePoint Pharmaceuticals, Inc. has a 12-month low of $5.67 and a 12-month high of $30.99. The firm’s 50-day moving average price is $8.76 and its 200-day moving average price is $12.50. The stock has a market capitalization of $434.38 million, a price-to-earnings ratio of -4.58 and a beta of 1.59.

EyePoint Pharmaceuticals (NASDAQ:EYPT) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.03). EyePoint Pharmaceuticals had a negative return on equity of 43.24% and a negative net margin of 172.29%. The firm had revenue of $9.48 million for the quarter, compared to analysts’ expectations of $11.61 million. On average, equities analysts predict that EyePoint Pharmaceuticals, Inc. will post -2.33 EPS for the current fiscal year.

Insider Transactions at EyePoint Pharmaceuticals

In other news, Director David R. Guyer sold 11,625 shares of EyePoint Pharmaceuticals stock in a transaction on Friday, July 12th. The stock was sold at an average price of $10.06, for a total transaction of $116,947.50. Following the completion of the sale, the director now directly owns 1,850 shares in the company, valued at $18,611. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 4.74% of the company’s stock.

Analysts Set New Price Targets

EYPT has been the subject of a number of analyst reports. HC Wainwright reiterated a “buy” rating and issued a $30.00 price target on shares of EyePoint Pharmaceuticals in a research note on Thursday, June 27th. StockNews.com upgraded EyePoint Pharmaceuticals to a “sell” rating in a research report on Saturday. JPMorgan Chase & Co. lowered their price target on EyePoint Pharmaceuticals from $32.00 to $29.00 and set an “overweight” rating on the stock in a report on Tuesday, August 13th. Jefferies Financial Group initiated coverage on EyePoint Pharmaceuticals in a research note on Wednesday, August 28th. They issued a “buy” rating and a $15.00 price target for the company. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of EyePoint Pharmaceuticals in a research report on Thursday, June 20th. One research analyst has rated the stock with a sell rating and eight have issued a buy rating to the stock. According to data from MarketBeat, EyePoint Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $30.57.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.